Terbinafine

Pharmacogenomic Information in the Context of the FDA-Approved Drug Label*

Terbinafine is an antifungal drug used for the treatment of onychomycosis of the toenail or fingernail due to dermatophytes (tinea unguium). It is an inhibitor of CYP2D6.

The FDA recommends, but does not require, genetic testing prior to initiating or reinitiating treatment with Terbinafine.

Excerpts from the Terbinafine (Lamisil) drug label:
"Terbinafine is an inhibitor of CYP4502D6 isozyme and has an effect on metabolism of desipramine, cimetidine, fluconazole, cyclosporine, rifampin, and caffeine."

"There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral terbinafine and warfarin, however, a causal relationship between Lamisil Tablets and these changes has not been established."

For the complete drug label text with sections containing pharmacogenetic information highlighted, see the Terbinafine (Lamisil) drug label PDF.